Terns Pharmaceuticals (TERN) Price & Analysis

Compare

465 Followers

TERN Stock Chart & Stats

$29.36

-$0.29(-5.06%)

At close: Jan 08 4:00 PM EST

$29.36

-$0.29(-5.06%)

Day’s Range― - ―

52-Week Range$1.87 - $30.25

Previous CloseN/A

Volume294.76K

Average Volume (3M)4.59M

Market Cap

$2.64B

Enterprise Value$394.07M

Total Cash (Recent Filing)$295.63M

Total Debt (Recent Filing)$1.03M

Price to Earnings (P/E)―

Beta1.38

Next Earnings

Mar 31, 2026

EPS Estimate

-0.3

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding90,079,780

10 Day Avg. Volume2,980,464

30 Day Avg. Volume4,587,166

Financial Highlights & Ratios

PEG Ratio0.42

Price to Book (P/B)1.27

Price to Sales (P/S)0.00

P/FCF Ratio-6.29

Enterprise Value/Market Cap0.15

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-3.65K

Enterprise Value/Ebitda-3.88

Forecast

1Y Price Target

$27.80

Price Target Upside-5.31% Downside

Rating ConsensusStrong Buy

Number of Analyst Covering12

EPS Forecast (FY)-1.09

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessInitial efficacy results from the Phase I CARDINAL study in CML represent the best-case scenario for TERN-701.

Financial StabilityCash of $295M provides runway through 2028.

Market PotentialTERN-701 has the potential to challenge the dominant market share currently held by Scemblix.

Bears Say

Competitive PositioningThe latest dataset underscores several emerging questions about TERN-701's differentiation, competitive durability, and strategic positioning within the CML landscape.

Product Development ChallengesIn terms of safety, there were two patients with drug related liver toxicity, which led to the decision not to advance TERN-601.

Product PerformanceTerns reported relatively lackluster topline 12-week results from its Phase 2 trial of TERN-601, a once-daily oral GLP-1 for obesity.

Terns Pharmaceuticals News

Terns Pharmaceuticals price target raised to $35 from $25 at Citizens JMP

Citizens JMP raised the firm’s price target on Terns Pharmaceuticals (TERN) to $35 from $25 and keeps an...

12d ago

TERN

Terns Pharmaceuticals price target raised to $36 from $28 at Barclays

Barclays analyst Etzer Darout raised the firm’s price target on Terns Pharmaceuticals (TERN) to $36 from $28 and...

13d ago

TERN

Terns Pharmaceuticals price target raised to $35 from $28 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Terns Pharmaceuticals (TERN) to $35 from $28 and...

19d ago

TERN

Terns Pharmaceuticals price target raised to $30 from $22 at BMO Capital

BMO Capital raised the firm’s price target on Terns Pharmaceuticals (TERN) to $30 from $22 and keeps an...

20d ago

TERN

Terns Pharmaceuticals price target raised to $33 from $32 at Mizuho

Mizuho analyst Graig Suvannavejh raised the firm’s price target on Terns Pharmaceuticals (TERN) to $33 from $32 and...

25d ago

TERN

Terns Pharmaceuticals price target raised to $28 from $27 at Barclays

Barclays raised the firm’s price target on Terns Pharmaceuticals (TERN) to $28 from $27 and keeps an Overweight...

27d ago

TERN

Terns Pharmaceuticals reports Q3 EPS (27c), consensus (30c)

“We’re thrilled with the positive momentum of the CARDINAL program generated by the unprecedented Phase 1 MMR achievement...

27d ago

TERN

Promising Outlook for TERN-701 in CML Market: Buy Rating Affirmed by Analyst

William Blair analyst Andy Hsieh has maintained their bullish stance on TERN stock, giving a Buy rating yesterday....

18d ago

TERN

Terns Pharmaceuticals: Promising Clinical Results and Strong Financial Position Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on TERN stock, giving a Buy rating today....

24d ago

TERN

Terns Pharmaceuticals Reports Q3 2025 Results and Updates

Terns Pharmaceuticals, Inc. ( ($TERN) ) has released its Q3 earnings. Here is a breakdown of the information...

26d ago

TERN

Promising Outlook for Terns Pharmaceuticals: Buy Rating Backed by Strong Financials and Potential Breakthrough in Leukemia Treatment

William Blair analyst Andy Hsieh has reiterated their bullish stance on TERN stock, giving a Buy rating on...

27d ago

TERN

Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV

The major averages were broadly lower at midday, reflecting mounting concerns over valuations and unclear central-bank policy. Heightening...

1M ago

CZR

HTZ

Terns Pharmaceuticals price target raised to $22 from $15 at BMO Capital

BMO Capital raised the firm’s price target on Terns Pharmaceuticals (TERN) to $22 from $15 and keeps an...

1M ago

TERN

Terns Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein upgraded Terns Pharmaceuticals (TERN) to Buy from Neutral with a $20 price target...

1M ago

TERN

TERN FAQ

What was Terns Pharmaceuticals’s price range in the past 12 months?

Terns Pharmaceuticals lowest stock price was $1.86 and its highest was $30.25 in the past 12 months.

What is Terns Pharmaceuticals’s market cap?

Terns Pharmaceuticals’s market cap is $2.64B.

When is Terns Pharmaceuticals’s upcoming earnings report date?

Terns Pharmaceuticals’s upcoming earnings report date is Mar 31, 2026 which is in 113 days.

How were Terns Pharmaceuticals’s earnings last quarter?

Terns Pharmaceuticals released its earnings results on Nov 10, 2025. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.294 by $0.024.

Is Terns Pharmaceuticals overvalued?

According to Wall Street analysts Terns Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Terns Pharmaceuticals pay dividends?

Terns Pharmaceuticals does not currently pay dividends.

What is Terns Pharmaceuticals’s EPS estimate?

Terns Pharmaceuticals’s EPS estimate is -0.3.

How many shares outstanding does Terns Pharmaceuticals have?

Terns Pharmaceuticals has 90,079,780 shares outstanding.

What happened to Terns Pharmaceuticals’s price movement after its last earnings report?

Terns Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.294. Following the earnings report the stock price went up 7.636%.

Which hedge fund is a major shareholder of Terns Pharmaceuticals?

Currently, no hedge funds are holding shares in TERN

Terns Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-29.12%

Trailing 12-Months

Asset Growth

-20.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Terns Pharmaceuticals

Terns Pharmaceuticals (TERN) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for the treatment of liver diseases and cancer. The company focuses on addressing significant unmet medical needs by advancing a robust pipeline of small-molecule therapeutics. Terns Pharmaceuticals operates within the healthcare sector, specifically targeting conditions such as non-alcoholic steatohepatitis (NASH) and other liver-related diseases, utilizing its expertise in drug discovery and development.

Terns Pharmaceuticals (TERN) Earnings & Revenues

Historic Earnings Reports

TERN Stock 12 Month Forecast

Average Price Target

$27.80

▼(-5.31% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","10":"$10","19":"$19","28":"$28","37":"$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$36.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,10,19,28,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.26,10.393846153846154,12.527692307692309,14.661538461538463,16.795384615384616,18.92923076923077,21.063076923076927,23.196923076923078,25.330769230769235,27.464615384615385,29.598461538461542,31.732307692307693,33.86615384615385,{"y":36,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.26,9.763076923076923,11.266153846153845,12.769230769230768,14.272307692307692,15.775384615384615,17.278461538461535,18.78153846153846,20.284615384615385,21.787692307692307,23.29076923076923,24.793846153846154,26.296923076923072,{"y":27.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.26,8.778461538461539,9.296923076923077,9.815384615384616,10.333846153846153,10.852307692307694,11.37076923076923,11.88923076923077,12.407692307692308,12.926153846153847,13.444615384615386,13.963076923076922,14.481538461538463,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.94,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.81,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.26,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >